journal article·2019-12-04Open access

Inhibiting tumour metastasis by DQA modified paclitaxel plus ligustrazine micelles in treatment of non-small-cell lung cancer

Hong-Jun Xie, Jing Zhao, DongZhi Zhuo-Ma, NorBu Zhan-Dui, Aga Er-Bu, Tashi Tsering

Abstract

Lung cancer is a kind of malignant tumour characterized as uncontrolled cell growth in lung. These malignant cell growth can spread beyond the lung by process of metastasis into other tissues or parts of the body. In this study, we developed dequalinium (DQA) modified paclitaxel plus ligustrazine micelles to destroy vasculogenic mimicry (VM) channels and inhibit tumour metastasis. In vitro assays showed that the targeting micelles with centralized particle size distribution showed not only vigoroso cytotoxicity on A549 cells but also strong inhibition on VM channels and tumour metastasis. Mechanism studies indicated that the DQA modified paclitaxel plus ligustrazine micelles could down-regulate the expressions of VEGF, MMP2, TGF-β1 and E-cadherin in A549 cells. In vivo assays indicated that the targeting drug-loaded micelles could enhance the accumulation of chemotherapeutic drugs at tumour sites and exhibit strong tumour inhibitory activity with negligible toxicity. Hence, the DQA modified paclitaxel plus ligustrazine micelles developed in this study may provide a potential strategy for treatment of NSCLC.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Cancer Cells and Metastasis · Nanoparticle-Based Drug Delivery · Radiopharmaceutical Chemistry and Applications

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Innovation Center for Traditional Tibetan Medicine Modernization and Quality Control, Medicine College of Tibet University

Traditional Tibetan Medical Research and Study Institute of Regional Traditional Tibetan Medical Hospital

Funding

Project of Scientific and Technological Plan of Tibetan Medicine Administration of Tibet Autonomous Region

References (36)

Show source-provided references
1. 10.1007/978-3-319-24223-1_110.1007/978-3-319-24223-1_1 ↗
2. 10.3109/21691401.2015.105246610.3109/21691401.2015.1052466 ↗
3. 10.5306/wjco.v5.i2.10310.5306/wjco.v5.i2.103 ↗
4. 10.3322/canjclin.24.4.23810.3322/canjclin.24.4.238 ↗
5. 10.1002/advs.20160022910.1002/advs.201600229 ↗
6. 10.1021/acs.molpharmaceut.7b0085510.1021/acs.molpharmaceut.7b00855 ↗
7. 10.1159/00048611610.1159/000486116 ↗
8. 10.1007/s10549-016-3736-910.1007/s10549-016-3736-9 ↗
9. Wang HY, Zhang XR. Comparison of efficacy and safety between liposome-paclitaxel injection plus carboplatin and paclitaxel plus carboplatin as first line treatment in advanced non-small cell lung cancer. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2014;36:305–308.
10. 10.1080/21691401.2018.148108210.1080/21691401.2018.1481082 ↗
11. 10.1021/jacs.7b0906010.1021/jacs.7b09060 ↗
12. 10.1080/03639045.2017.130495610.1080/03639045.2017.1304956 ↗
13. 10.1016/j.ejpb.2013.08.00310.1016/j.ejpb.2013.08.003 ↗
14. 10.1016/j.biopha.2014.12.02810.1016/j.biopha.2014.12.028 ↗
15. 10.1021/acs.jmedchem.7b0109610.1021/acs.jmedchem.7b01096 ↗
16. Shen J, Zeng L, Pan L, et al. Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3. Oncol Lett. 2018;15:4557–4563.
17. Zheng CY, Xiao W, Zhu MX, et al. Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and invasion and metastasis. Int J Oncol. 2012;40:2029–2037.
18. 10.3892/or.2012.186610.3892/or.2012.1866 ↗
19. 10.1021/acsmacrolett.7b0049010.1021/acsmacrolett.7b00490 ↗
20. 10.3109/1061186X.2014.97982910.3109/1061186X.2014.979829 ↗
21. 10.1016/j.sjbs.2017.03.00510.1016/j.sjbs.2017.03.005 ↗
22. 10.1016/j.sjbs.2017.12.01110.1016/j.sjbs.2017.12.011 ↗
23. 10.1016/j.adro.2017.11.00310.1016/j.adro.2017.11.003 ↗
24. 10.1177/088532821668575510.1177/0885328216685755 ↗
25. 10.3892/ol.2016.545810.3892/ol.2016.5458 ↗
26. 10.18632/oncotarget.2361610.18632/oncotarget.23616 ↗
27. 10.18632/oncotarget.2378510.18632/oncotarget.23785 ↗
28. 10.1016/j.canlet.2016.04.01410.1016/j.canlet.2016.04.014 ↗
29. 10.1158/0008-5472.CAN-14-185510.1158/0008-5472.CAN-14-1855 ↗
30. 10.1080/1061186X.2018.142880910.1080/1061186X.2018.1428809 ↗
31. 10.3389/fphys.2017.0113210.3389/fphys.2017.01132 ↗
32. Rivera-Pérez J, Monter-Vera MDR, Barrientos-Alvarado C, et al. Evaluation of VEGF and PEDF in prostate cancer: a preliminary study in serum and biopsies. Oncol Lett. 2018;15:1072–1078.
33. Lu S, Zhang Z, Chen M, et al. Silibinin inhibits the migration and invasion of human gastric cancer SGC7901 cells by downregulating MMP-2 and MMP-9 expression via the p38MAPK signaling pathway. Oncol Lett. 2017;14:7577–7582.
34. 10.1007/s12013-015-0673-x10.1007/s12013-015-0673-x ↗
35. 10.1186/s12935-014-0072-110.1186/s12935-014-0072-1 ↗
36. 10.1007/s00018-015-1977-010.1007/s00018-015-1977-0 ↗